GlassScriptPhysician profile
Christopher William Lobo
NPI 1639665367
$3,680.23
in general payments reported to CMS, 2019-2025
28 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $821 · 2023: $1,315 · 2024: $1,143 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,720.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $613.41 | 2021-2025 | |
| Amgen INC. | $507.55 | 2022-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $475.08 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $305.40 | 2022-2024 | Ninlaro |
| Novartis Pharmaceuticals Corporation | $245.00 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.07 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $175.66 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $173.83 | 2022-2024 | Mounjaro, Trulicity, Jardiance |
| Medtronic, INC. | $139.41 | 2023 | Corevalve Evolut R |
| Astrazeneca Pharmaceuticals LP | $125.46 | 2022-2025 | Breztri, Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $88.73 | 2022-2025 | Opdivo |
| Otsuka America Pharmaceutical, INC. | $82.93 | 2023-2024 | Rexulti |
| Pfizer INC. | $63.82 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $58.98 | 2023-2025 | Gemtesa, Orgovyx |
| Lundbeck LLC | $50.82 | 2023-2024 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $50.09 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $48.69 | 2022-2024 | Xarelto |
| Exact Sciences Corporation | $44.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $42.37 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $38.30 | 2024 | Austedo Xr |
| Boston Scientific Corporation | $26.20 | 2024 | Watchman Access System |
| Vertex Pharmaceuticals Incorporated | $19.74 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.25 | 2025 | Caplyta |
| Dexcom, INC. | $17.35 | 2025 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $16.27 | 2025 | Yupelri |
| Exeltis, USA INC. | $14.90 | 2023 | Slynd |
| Sanofi-Aventis U.S. LLC | $14.52 | 2022 | |
| Axsome Therapeutics, INC. | $14.00 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lobo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.